Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.

Many patients with overweight or obesity discontinue glucagon-like peptide-1 receptor agonist therapy within one year.

While some orthopedic and spine surgeons are divided on how medications used for weight loss, including Ozempic and Wegovy, will shape the field, it is undeniable that the drugs are playing an ...

Two Omaha women lost more than 300 lbs. combined with injections of a GLP-1 drug, which are used increasingly for weight loss ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. GLP-1 agonist drugs like Ozempic and Wegovy have surged in popularity during the last ...

One participant lost 22% of her weight in nine months — substantially faster than the rate seen with approved GLP-1 drugs ...